Literature DB >> 33746450

Long-term Management of the Adult Liver Transplantation Recipients.

Narendra S Choudhary1, Neeraj Saraf1, Sanjiv Saigal1, Arvinder S Soin1.   

Abstract

The survival of liver transplantation (LT) recipients has been improved remarkably in short-term. The major causes of mortality in long-term include nonimmunological causes such as cardiovascular, de novo malignancy, chronic kidney disease, and recurrence of primary disease. Rejection-related mortality is rare in the long-term after LT. We discuss nonrejection causes of long-term morbidity/mortality, risk factors, and management strategies in LT recipients. In addition, we discuss osteoporosis, contraception, and pregnancy in LT recipients.
© 2020 Indian National Association for Study of the Liver. Published by Elsevier B.V.

Entities:  

Keywords:  AIH, autoimmune hepatitis; BMI, body mass index; CKD, chronic kidney disease; CNI, calcineurin inhibitors; CVD, cardiovascular disease; DDLT, deceased donor liver transplantation; DM, diabetes mellitus; DNM, de novo malignancy; HCV, hepatitis C virus; HR, hazard ratio; IUCD, Intrauterine contraceptive devices; LDLT, living donor liver transplantation; LT, liver transplantation; MDRD, Modification of Diet in Renal Disease; MMF, mycophenolate; MS, metabolic syndrome; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; OR, odds ratio; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; PTDM, posttransplantation diabetes mellitus; PTMS, posttransplantation metabolic syndrome; SVR, sustained virological response; cardiovascular disease; de novo malignancy; eGFR, estimated glomerular filtration rate; mTORi, Mammalian target of rapamycin inhibitors; osteoporosis; pregnancy; recurrence

Year:  2020        PMID: 33746450      PMCID: PMC7953009          DOI: 10.1016/j.jceh.2020.06.010

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  135 in total

Review 1.  Overview of immunosuppression in liver transplantation.

Authors:  Anjana A Pillai; Josh Levitsky
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

2.  Liver transplantation for overlap syndromes of autoimmune liver diseases.

Authors:  Rahima A Bhanji; Andrew L Mason; Safwat Girgis; Aldo J Montano-Loza
Journal:  Liver Int       Date:  2012-11-12       Impact factor: 5.828

3.  Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis.

Authors:  Chandra Bhati; Michael O Idowu; Arun J Sanyal; Maria Rivera; Carolyn Driscoll; Richard T Stravitz; Divyanshoo R Kohli; Scott Matherly; Puneet Puri; HoChong Gilles; Adrian Cotterell; Marlon Levy; Richard K Sterling; Velimir A Luketic; Hannah Lee; Amit Sharma; Mohammad Shadab Siddiqui
Journal:  Transplantation       Date:  2017-08       Impact factor: 4.939

4.  Chronic kidney disease and associated mortality after liver transplantation--a time-dependent analysis using measured glomerular filtration rate.

Authors:  Alina M Allen; W Ray Kim; Terry M Therneau; Joseph J Larson; Julie K Heimbach; Andrew D Rule
Journal:  J Hepatol       Date:  2014-04-05       Impact factor: 25.083

5.  Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.

Authors:  Eric M Yoshida; Paul J Marotta; Paul D Greig; Norman M Kneteman; Denis Marleau; Marcelo Cantarovich; Kevork M Peltekian; Leslie B Lilly; Charles H Scudamore; Vincent G Bain; William J Wall; Andre Roy; Robert F Balshaw; Jeffrey S T Barkun
Journal:  Liver Transpl       Date:  2005-09       Impact factor: 5.799

6.  Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus.

Authors:  Harini A Chakkera; William C Knowler; Yugandhara Devarapalli; E Jennifer Weil; Raymond L Heilman; Amylou Dueck; David C Mulligan; Kunam S Reddy; Adyr A Moss; Kristin L Mekeel; Marek J Mazur; Khaled Hamawi; Janna C Castro; Curtiss B Cook
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-17       Impact factor: 8.237

Review 7.  Incidence, risk factors and outcomes of de novo malignancies post liver transplantation.

Authors:  Pavan Kedar Mukthinuthalapati; Raghavender Gotur; Marwan Ghabril
Journal:  World J Hepatol       Date:  2016-04-28

8.  Chronic kidney disease after liver transplantation: pretransplantation risk factors and predictors during follow-up.

Authors:  Michela Giusto; Marina Berenguer; Carlo Merkel; Victoria Aguilera; Angel Rubin; Stefano Ginanni Corradini; Gianluca Mennini; Massimo Rossi; Martin Prieto; Manuela Merli
Journal:  Transplantation       Date:  2013-05-15       Impact factor: 4.939

Review 9.  Systematic review: recurrent autoimmune liver diseases after liver transplantation.

Authors:  A J Montano-Loza; R A Bhanji; S Wasilenko; A L Mason
Journal:  Aliment Pharmacol Ther       Date:  2016-12-12       Impact factor: 8.171

10.  Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial.

Authors:  P De Simone; F Nevens; L De Carlis; H J Metselaar; S Beckebaum; F Saliba; S Jonas; D Sudan; J Fung; L Fischer; C Duvoux; K D Chavin; B Koneru; M A Huang; W C Chapman; D Foltys; S Witte; H Jiang; J M Hexham; G Junge
Journal:  Am J Transplant       Date:  2012-08-06       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.